Key Points
- ARS Pharmaceuticals insider Alexander Fitzpatrick sold 3,355 shares on June 12 at an average price of $10.00, totaling $33,550. The trade was made under a pre-arranged Rule 10b5-1 plan, and his holdings fell by 3.56%.
- The stock opened at $9.76 and has traded between a 1-year low of $6.66 and high of $18.90. ARS Pharmaceuticals currently has a market cap of about $969 million.
- Wall Street remains cautiously positive on SPRY, with four Buy ratings and a consensus Moderate Buy rating. Analysts’ average price target is $28.60, well above the current share price.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Alexander Fitzpatrick sold 3,355 shares of the company's stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the sale, the insider owned 90,910 shares in the company, valued at approximately $909,100. This trade represents a 3.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ARS Pharmaceuticals Price Performance
Shares of NASDAQ SPRY opened at $9.76 on Friday. ARS Pharmaceuticals, Inc. has a 1-year low of $6.66 and a 1-year high of $18.90. The company has a market cap of $969.17 million, a price-to-earnings ratio of -4.86 and a beta of 0.94. The company has a debt-to-equity ratio of 2.79, a current ratio of 4.94 and a quick ratio of 4.77. The stock's 50-day moving average is $8.42 and its two-hundred day moving average is $9.33.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. The business had revenue of $22.68 million during the quarter, compared to analysts' expectations of $22.20 million. Analysts forecast that ARS Pharmaceuticals, Inc. will post -1.89 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on SPRY shares. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, March 10th. Cantor Fitzgerald increased their price objective on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, May 28th. Wall Street Zen upgraded ARS Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Northland Securities started coverage on ARS Pharmaceuticals in a report on Thursday, April 9th. They issued an "outperform" rating and a $25.00 price objective on the stock. Finally, Weiss Ratings upgraded ARS Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 1st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $28.60.
Read Our Latest Analysis on SPRY
Institutional Trading of ARS Pharmaceuticals
A number of large investors have recently made changes to their positions in SPRY. Torren Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company's stock valued at $56,000 after purchasing an additional 982 shares during the period. Bessemer Group Inc. boosted its position in shares of ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company's stock valued at $61,000 after purchasing an additional 7,290 shares during the period. Osterweis Capital Management Inc. acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $65,000. Finally, Russell Investments Group Ltd. boosted its position in shares of ARS Pharmaceuticals by 197.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company's stock valued at $67,000 after purchasing an additional 4,427 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
